淋巴瘤患者在 CAR-T 细胞治疗试验与一般人群之间的差异

Chimeric antigen receptor (CAR)-T cell therapies appear to be promising treatments for non-Hodgkin's and B-cell lymphoma.

However, several CAR-T therapies approved by the US Food and Drug Administration have only been tested for efficacy in relatively few single-arm clinical trials with small sample sizes.

We sought to examine the differences between patients in these trials and the general population of patients with non-Hodgkin's and B-cell lymphoma. Five hundred and twenty-two patients from 15 CAR-T trials found in a systematic review and 417,492 patients from the Surveillance, Epidemiology, and End Results (SEER) Program database were compared. CAR-T study participants appeared to be younger (46. 7% under 70 years old vs. 42. 2%), more male (68. 0% vs. 55. 7%), and followed for a shorter period of time compared to patients in the SEER population (mean [M] 45.

6 months, 95% confidence interval [CI] 17. 7 to 63. 3 months follow-up vs. M 57. 1 months, 95% CI 57. 0 to 57. 3 months survival). CAR-T study participants may differ significantly from the general population of patients with non-Hodgkin's and B-cell lymphoma. Effectiveness of CAR-T therapies in the general population of lymphoma patients may differ from effectiveness demonstrated in trials. Newly created CAR-T patient registries are essential to establishing population-level effectiveness of the therapies.